Acta Biochimica Polonica

Acta Biochimica Polonica is the official journal of the Polish Biochemical Society, published on the Frontiers publishing platform, and it carries biochemistry that reaches from the laboratory bench toward clinical use.《波兰生物化学学报》是波兰生物化学学会的机关刊物，在 Frontiers 出版平台上发行，刊载从实验室台面一路通向临床应用方向的生物化学工作。

In the 2025 edition of the journal citation report the title holds an impact factor of 2.2, and the platform records a CiteScore of 4.8 for a journal that publishes some fifteen papers a year.在 2025 年版期刊引证报告中，该刊影响因子为 2.2，平台为该刊记录的 CiteScore 为 4.8，一年约刊出十五篇论文。

Scope

• The journal presents itself as a multidisciplinary open access title in biochemistry, and it takes work that joins a laboratory finding to the clinical question it answers.该刊自我定位为生物化学领域的多学科开放获取刊物，收载把实验室发现与它所回应的临床问题接合起来的工作。

• Enzymology and metabolism stand among the areas named first, so an enzyme and the pathway it drives are central matter for the journal.酶学与代谢属于最先点名的方向，酶以及它所驱动的代谢通路因而是该刊的核心题材。

• Membranes and bioenergetics form a second named area, and the journal takes work on how a membrane captures and moves energy.膜与生物能学构成第二个点名方向，该刊接纳膜如何获取与转移能量方面的工作。

• Gene structure and expression make up a third, and the way a gene is organised, read and regulated falls inside the remit.基因结构与表达构成第三个方向，基因如何组织、如何被读取与如何被调控都在收稿范围之内。

• The structure and metabolism of proteins, nucleic acids and carbohydrates complete the stated interests, so a folded protein and a strand of RNA are equally at home.蛋白质、核酸与碳水化合物的结构及代谢补足了自述的选题清单，折叠的蛋白质与一段 RNA 在同等程度上都属于其题材。

• The journal states plainly that a manuscript which does not treat biochemistry or a direct application of it is not suitable, and that boundary keeps the title on its own ground.该刊明确声明，不以生物化学或其直接应用为题的稿件不予考虑，这条界限使刊物守住自身的题材领域。

• A run of work on drug discovery and on natural compounds sits inside that boundary, and the masthead gathers special issues on chemical compounds for cancer treatment and on biomarkers of inherited disease.药物发现与天然产物方面的一批工作落在这一界限之内，编务清单汇集了面向癌症治疗的化合物以及遗传病生物标志物等专号。

• Contributions that bear on the Sustainable Development Goals are invited, and the journal names good health and well-being, industry and innovation, and quality education as the aims it advances.与可持续发展目标相关的工作受到约请，该刊点名良好健康与福祉、产业创新与基础设施以及优质教育为其所推进的目标。

• Original research and full reviews form the main body of the journal, and a systematic review is filed as a class of its own.原创研究与完整综述构成该刊主体，系统性综述单列为一类。

• Shorter forms are taken as well, with the brief research report, the mini review, the opinion and the perspective each carrying its own label.较短的体裁同样收载，简报、小型综述、观点与展望各有自己的标识。

• An editorial introduces a special issue and is published without charge, so a guest editor can open a collection freely.社论用于引出专号，且免费发表，客座编辑因而可以无偿地开启一组文章。

• Special issues gather peer-reviewed collections around one theme, and each one is organised by guest editors who bring a group of researchers together.专号围绕单一主题汇集经同行评议的文章，每一本由客座编辑组织，把一批研究者聚到一处。

• The readership runs from working biochemists to clinical scientists, and the journal is written for a laboratory that wants to see a discovery put to use.读者从一线生物化学工作者延伸到临床科研人员，该刊面向希望把发现付诸应用的实验室写作。

• Its subject headings in the literature indexes are narrow, the journal being filed under biochemistry and molecular biology.该刊在文献索引中的主题归类较窄，被列于生物化学与分子生物学之下。

History

• The journal began in 1954 in Warsaw, and the first volume opened a run whose numbering still tracks the calendar year, so that volume 73 falls in 2026.该刊 1954 年创办于华沙，第一卷开启的卷号序列至今仍与日历年同步，故第 73 卷对应 2026 年。

• Its ISSN record names the earliest publisher as the Committee of Biochemistry and Biophysics of the Polish Academy of Sciences together with the Polish Biochemical Society, both in Warsaw.其 ISSN 记录把最早的出版者记为波兰科学院生物化学与生物物理委员会与波兰生物化学学会，二者均位于华沙。

• The Polish Biochemical Society, which counts the journal as its organ, was established in 1958, and the journal has carried the society's name on its masthead through the decades since.把该刊视为机关刊物的波兰生物化学学会成立于 1958 年，此后数十年间该刊一直在刊头署上学会之名。

• The medical literature catalogue has tracked the title since the middle of the 1960s, and it records coverage from volume 12 in 1965 for both MEDLINE and PubMed, together with Index Medicus and OLDMEDLINE.医学文献目录自 1960 年代中期起追踪该刊，其记载的 MEDLINE 与 PubMed 收录自 1965 年第 12 卷起，Index Medicus 与 OLDMEDLINE 一并著录。

• For most of its life the journal appeared in print and then online under the society's own imprint, and the older records are registered under the 10.18388/abp prefix.该刊大半生以学会自有印本先出纸本再上网络，较早的记录登记在 10.18388/abp 前缀之下。

• A change of platform came in 2023, when Frontiers signed its first open access publishing agreement in Poland with the Polish Biochemical Society.2023 年出现一次平台更替，Frontiers 与波兰生物化学学会签下该公司在波兰的第一份开放获取出版协议。

• Submissions opened on the new platform in August 2023, and the first papers under the agreement were published in January 2024, the ISSN transfer taking effect on the first day of that year.新平台于 2023 年 8 月开放投稿，协议下的首批论文在 2024 年 1 月发表，ISSN 移交自当年元旦生效。

• On the Frontiers platform the journal is published gold open access under a Creative Commons Attribution licence, and authors keep the copyright of their articles.在 Frontiers 平台上该刊以知识共享署名许可的完全开放获取方式出版，作者保留其文章的版权。

• The editorial office now sits in Lausanne, and new records carry the 10.3389/abp prefix while the whole back run stays readable.编辑部现设于洛桑，新记录使用 10.3389/abp 前缀，而全部过刊仍然可读。

• The journal has kept a quarterly rhythm through its life, and the current platform states quarterly publication as the frequency.该刊一路保持季刊节律，现行平台也把季刊列为出版频率。

• Supplement issues have carried conference material, and a 2022 supplement gathered the book of abstracts of a conference on non-coding RNA held in Poznań.增刊曾承载会议材料，2022 年的一期增刊汇集了在波兹南举行的一场非编码 RNA 会议的摘要集。

• The impact factor has moved from 2.149 in 2021 to 2.349 in 2022, then to 1.4 in 2023, 1.7 in 2024 and 2.2 in 2025, and the platform reports a CiteScore of 4.8.影响因子由 2021 年的 2.149 升至 2022 年的 2.349，其后为 2023 年的 1.4、2024 年的 1.7 与 2025 年的 2.2，平台另给出 CiteScore 为 4.8。

• The 2025 citation report places the journal in the fourth quartile of biochemistry and molecular biology, ranked 258 of 328 titles, in a field that publishes some fifteen papers a year.2025 年的引证报告把该刊列于生物化学与分子生物学类目第四区，在 328 种期刊中排第 258 位，该领域一年约刊出十五篇论文。

• A supplement still appears each year to carry abstracts, and the title keeps its own retrospective archive online alongside the current volume.该刊每年仍出一期承载摘要的增刊，并让自身的回顾性档案与现行卷次一起在线保存。

Editors

• The chief editor is Grzegorz Węgrzyn of the University of Gdansk, and the platform lists him as leading the editorial work of the journal.主编为格但斯克大学的（Grzegorz Węgrzyn），平台把他列为领导该刊编务的人。

• An advisory board of nineteen members stands alongside him, drawn from Poland, Europe and the United States.他身边设有一个十九人的顾问委员会，成员来自波兰、欧洲与美国。

• Among the advisers are Grzegorz Bartosz of the University of Rzeszów and Janusz Błasiak of the University of Lodz, and the board reaches abroad with Michael Jonathan Davies of the University of Copenhagen and Andrzej T. Slominski of the University of Alabama at Birmingham.顾问中有热舒夫大学的（Grzegorz Bartosz）与罗兹大学的（Janusz Błasiak），委员会也延伸到国外，哥本哈根大学的（Michael Jonathan Davies）与伯明翰阿拉巴马大学的（Andrzej T. Slominski）均在其列。

• Other advisers sit at Macquarie University in Australia, Umeå University in Sweden and the Norwegian University of Life Sciences, so the board spans four continents.另有一些顾问任职于澳大利亚的麦考瑞大学、瑞典的于默奥大学与挪威生命科学大学，委员会因而横跨四大洲。

• The platform carries a large editorial board besides the advisers, numbering about one hundred and seventy names under the heading of associate editors and reviewers.顾问之外，平台还列有一个庞大的编委会，在副编辑与审稿人标题下约有 170 个名字。

• Those associate editors reach from Uppsala University in Sweden to Case Western Reserve University in the United States and the Jagiellonian University in Kraków.这些副编辑的分布自瑞典乌普萨拉大学延伸到美国凯斯西储大学与克拉科夫的雅盖隆大学。

• Full peer review runs in two phases, the first in which reviewers assess a manuscript independently of one another and the second in which authors and reviewers exchange comments in a discussion forum.完整同行评议分作两个阶段，前段由审稿人彼此独立地评阅稿件，后段由作者与审稿人在讨论区交换意见。

• A handling editor oversees the exchange, and the chief editor may join the forum when a case calls for it.责任编辑监督这一过程，必要时主编也会进入讨论区。

• The journal operates a single blind review, and a manuscript written by a section editor is handled so that the review of it stays hidden from that person, which keeps the process independent.该刊实行单盲评审，若稿件由某位栏目编辑所著，其评议对该人不可见，以保证程序的独立。

• Original research, review, systematic review and brief research report each go through the full process, while an editorial gets a shortened one that may rest with the handling editor alone.原创研究、综述、系统性综述与简报都走完整流程，社论则走简略流程，可能只由责任编辑裁定。

• A manuscript that fails international ethical standards is returned without scientific review, and at the editors' discretion a paper may be rejected after editorial assessment alone.不符国际伦理标准的稿件不经学术评议即退回，编辑也可自行裁量，仅凭编务评估就退稿。

• Publication is funded by an article processing charge, set at 1550 United States dollars for members of the Polish Biochemical Society and 1750 dollars for others on research and review articles.出版由文章处理费支撑，波兰生物化学学会会员的研究与综述类文章为 1550 美元，会外作者为 1750 美元。

• Shorter article types carry a lower charge, at 800 dollars for members and 900 dollars for others, and a special issue editorial is published free of charge.较短体裁的费用较低，会员为 800 美元、会外作者为 900 美元，专号社论则免费发表。

• Authors facing a charge may apply for support through the fee programme, and the society and its publisher present annual awards for the best paper, the best paper by a young investigator and the best review.面对费用有困难的作者可申请费用扶持，学会与出版方另设年度奖项，表彰最佳论文、最佳青年研究者论文与最佳综述。